Additionally, we assessed the anti-tumor activity of ARQ 092 in in vivo mouse models implanted with AN3CA cells (mutant PIK3R1, PTEN deficient, and activating mutation of FGFR2) [43], KPL-4 cells (over-expression of HER2 and mutation in PIK3CA) [44]; and ZR-75-1 cells (ER positive, PTEN deficient) [45, 46]. This evidence concerns the gene FGFR2 and neoplasm.